Pharmacotherapeutics of SARS-CoV-2 Infections

Bhavesh D. Kevadiya; Jatin Machhi; Jonathan Herskovitz; Maxim D. Oleynikov; Wilson R. Blomberg; Neha Bajwa; Dhruvkumar Soni; Srijanee Das; Mahmudul Hasan; Milankumar Patel; Ahmed M. Senan; Santhi Gorantla; Jo Ellyn McMillan; Benson Edagwa; Robert Eisenberg; Channabasavaiah B. Gurumurthy; St Patrick M. Reid; Chamindie Punyadeera; Linda Chang; Howard E. Gendelman

doi:10.1007/s11481-020-09968-x

Pharmacotherapeutics of SARS-CoV-2 Infections

Bhavesh D. Kevadiya, Jatin Machhi, Jonathan Herskovitz, Maxim D. Oleynikov, Wilson R. Blomberg, Neha Bajwa, Dhruvkumar Soni, Srijanee Das, Mahmudul Hasan, Milankumar Patel, Ahmed M. Senan, Santhi Gorantla, Jo Ellyn McMillan, Benson Edagwa, Robert Eisenberg, Channabasavaiah B. Gurumurthy, St Patrick M. Reid, Chamindie Punyadeera, Linda Chang, Howard E. Gendelman

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effective treatment options have emerged and now include repurposed antivirals, corticosteroids and virus-specific antibodies. The latter has included convalescence plasma and monoclonal antibodies. Complete viral eradication will be achieved through an effective, safe and preventative vaccine. To now provide a comprehensive summary for each of the pharmacotherapeutics and preventative strategies being offered or soon to be developed for SARS-CoV-2. Graphical abstract: [Figure not available: see fulltext.]

Original language	English (US)
Pages (from-to)	12-37
Number of pages	26
Journal	Journal of Neuroimmune Pharmacology
Volume	16
Issue number	1
DOIs	https://doi.org/10.1007/s11481-020-09968-x
State	Published - Mar 2021

Keywords

Antibodies
Antivirals
COVID-19 therapeutics
SARS-CoV-2
Vaccine

ASJC Scopus subject areas

Neuroscience (miscellaneous)
Immunology and Allergy
Immunology
Pharmacology

Access to Document

10.1007/s11481-020-09968-x

Cite this

Kevadiya, B. D., Machhi, J., Herskovitz, J., Oleynikov, M. D., Blomberg, W. R., Bajwa, N., Soni, D., Das, S., Hasan, M., Patel, M., Senan, A. M., Gorantla, S., McMillan, J. E., Edagwa, B., Eisenberg, R., Gurumurthy, C. B., Reid, S. P. M., Punyadeera, C., Chang, L., & Gendelman, H. E. (2021). Pharmacotherapeutics of SARS-CoV-2 Infections. Journal of Neuroimmune Pharmacology, 16(1), 12-37. https://doi.org/10.1007/s11481-020-09968-x

Kevadiya, BD, Machhi, J, Herskovitz, J, Oleynikov, MD, Blomberg, WR, Bajwa, N, Soni, D, Das, S, Hasan, M, Patel, M, Senan, AM, Gorantla, S , McMillan, JE , Edagwa, B, Eisenberg, R, Gurumurthy, CB , Reid, SPM, Punyadeera, C, Chang, L & Gendelman, HE 2021, 'Pharmacotherapeutics of SARS-CoV-2 Infections', Journal of Neuroimmune Pharmacology, vol. 16, no. 1, pp. 12-37. https://doi.org/10.1007/s11481-020-09968-x

@article{029f5d6435904dc1aa847be78f62dab2,

title = "Pharmacotherapeutics of SARS-CoV-2 Infections",

abstract = "The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effective treatment options have emerged and now include repurposed antivirals, corticosteroids and virus-specific antibodies. The latter has included convalescence plasma and monoclonal antibodies. Complete viral eradication will be achieved through an effective, safe and preventative vaccine. To now provide a comprehensive summary for each of the pharmacotherapeutics and preventative strategies being offered or soon to be developed for SARS-CoV-2. Graphical abstract: [Figure not available: see fulltext.]",

keywords = "Antibodies, Antivirals, COVID-19 therapeutics, SARS-CoV-2, Vaccine",

author = "Kevadiya, {Bhavesh D.} and Jatin Machhi and Jonathan Herskovitz and Oleynikov, {Maxim D.} and Blomberg, {Wilson R.} and Neha Bajwa and Dhruvkumar Soni and Srijanee Das and Mahmudul Hasan and Milankumar Patel and Senan, {Ahmed M.} and Santhi Gorantla and McMillan, {Jo Ellyn} and Benson Edagwa and Robert Eisenberg and Gurumurthy, {Channabasavaiah B.} and Reid, {St Patrick M.} and Chamindie Punyadeera and Linda Chang and Gendelman, {Howard E.}",

note = "Publisher Copyright: {\textcopyright} 2021, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2021",

month = mar,

doi = "10.1007/s11481-020-09968-x",

language = "English (US)",

volume = "16",

pages = "12--37",

journal = "Journal of Neuroimmune Pharmacology",

issn = "1557-1890",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Pharmacotherapeutics of SARS-CoV-2 Infections

AU - Kevadiya, Bhavesh D.

AU - Machhi, Jatin

AU - Herskovitz, Jonathan

AU - Oleynikov, Maxim D.

AU - Blomberg, Wilson R.

AU - Bajwa, Neha

AU - Soni, Dhruvkumar

AU - Das, Srijanee

AU - Hasan, Mahmudul

AU - Patel, Milankumar

AU - Senan, Ahmed M.

AU - Gorantla, Santhi

AU - McMillan, Jo Ellyn

AU - Edagwa, Benson

AU - Eisenberg, Robert

AU - Gurumurthy, Channabasavaiah B.

AU - Reid, St Patrick M.

AU - Punyadeera, Chamindie

AU - Chang, Linda

AU - Gendelman, Howard E.

PY - 2021/3

Y1 - 2021/3

N2 - The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effective treatment options have emerged and now include repurposed antivirals, corticosteroids and virus-specific antibodies. The latter has included convalescence plasma and monoclonal antibodies. Complete viral eradication will be achieved through an effective, safe and preventative vaccine. To now provide a comprehensive summary for each of the pharmacotherapeutics and preventative strategies being offered or soon to be developed for SARS-CoV-2. Graphical abstract: [Figure not available: see fulltext.]

AB - The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effective treatment options have emerged and now include repurposed antivirals, corticosteroids and virus-specific antibodies. The latter has included convalescence plasma and monoclonal antibodies. Complete viral eradication will be achieved through an effective, safe and preventative vaccine. To now provide a comprehensive summary for each of the pharmacotherapeutics and preventative strategies being offered or soon to be developed for SARS-CoV-2. Graphical abstract: [Figure not available: see fulltext.]

KW - Antibodies

KW - Antivirals

KW - COVID-19 therapeutics

KW - SARS-CoV-2

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85099218143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099218143&partnerID=8YFLogxK

U2 - 10.1007/s11481-020-09968-x

DO - 10.1007/s11481-020-09968-x

M3 - Review article

C2 - 33403500

AN - SCOPUS:85099218143

SN - 1557-1890

VL - 16

SP - 12

EP - 37

JO - Journal of Neuroimmune Pharmacology

JF - Journal of Neuroimmune Pharmacology

IS - 1

ER -

Pharmacotherapeutics of SARS-CoV-2 Infections

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this